Skip to content

Efficacy of Dextrose Prolotherapy Compare With ESWT in the Treatment of Chronic Rotator Cuff Tendinopathy

Efficacy of Dextrose Prolotherapy Compare With Extracorporeal Shock Wave Therapy in the Treatment of Chronic Rotator Cuff Tendinopathy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06700746
Enrollment
24
Registered
2024-11-22
Start date
2023-11-10
Completion date
2024-11-20
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rotator Cuff Tendinopathy

Brief summary

To compare the efficacy of dextrose solution injection with ESWT for pain reduction in rotator cuff tendinopathy. Additionally, secondary objective is to evaluate DASH and active range of motion of shoulder joint

Interventions

PROCEDUREProlotherapy

Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions

Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic shoulder pain for at least 3 months * Unilateral affected side * History of unsuccessful conservative treatment * Age 18 years or older

Exclusion criteria

* Rotator cuff complete tear * Local or generalized arthritis * Previous shoulder surgery * Previous history allergy to local anesthesia * Pregnancy * Current infectious or tumorous disease * Dysfunction in the neck or thoracic region of both * Coagulation disturbance

Design outcomes

Primary

MeasureTime frameDescription
VAS scoreAssessment at baseline, three weeks, six weeks, three months and six months after the end of the treatmentPain reduction VAS

Secondary

MeasureTime frameDescription
Function DASH scoreAssessment at baseline, three weeks, six weeks, three months and six months after the end of the treatmentDisabilities of the arm, shoulder and hand
Shoulder ROMAssessment at baseline, three weeks, six weeks, three months and six months after the end of the treatmentActive range of motion: Forward flexion Abduction Internal rotation External rotation Active range of motion: Forward flexion Abduction Internal rotation External rotation Active range of motion: Forward flexion Abduction Internal rotation External rotation

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026